A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics.
Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks to based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and approximately 12 countries.

开始日期2025-08-07

申办/合作机构

AstraZeneca PLC

CTRI/2025/04/085048

/ Not yet recruiting临床3期

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with DapagliflozinAlone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure BaxDuo Prevent HF - BaxDuo Prevent HF

开始日期2025-04-28

申办/合作机构

AstraZeneca AB

[+1]

NCT06677060

/ Recruiting临床3期

A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF.
The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1.
Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation.
Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months.
The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD.
In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.

开始日期2025-03-14

申办/合作机构

AstraZeneca PLC

100 项与 Baxdrostat 相关的临床结果

登录后查看更多信息

100 项与 Baxdrostat 相关的转化医学

登录后查看更多信息

100 项与 Baxdrostat 相关的专利（医药）

登录后查看更多信息

项与 Baxdrostat 相关的文献（医药）

2025-08-01·JOURNAL OF HYPERTENSION

Breaking down resistance: novel aldosterone synthase inhibitors in the management of resistant hypertension

Article

作者: George, Jacob ; Kocherry, Cyril ; Eddison Chung Hung, Chai

This review aims to evaluate the impact of novel aldosterone synthase inhibitors, the first new class of antihypertensives in more than 20 years, on the management of resistant hypertension. We highlight the problem of resistant hypertension in clinical practice and describe the challenging history and development of aldosterone synthase inhibitors. The review highlights clinical trial evidence to-date for all agents in this class, with a key focus on the two most mature agents baxdrostat and lorundrostat which are currently in pivotal Phase 3 trials. Both agents have demonstrated significant dose-dependent reductions in blood pressure, particularly in patients with resistant hypertension and crucially, with a minimal impact on cortisol levels. They have also shown promise with marked blood pressure reductions in patients with varying physiological profiles and few adverse events at optimised doses. However, as would be expected, both drugs are associated with increases in serum potassium levels, necessitating careful monitoring.

2025-05-01·Cardiology in review

Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension

Review

作者: Frishman, William H. ; Dey, Subo ; Aronow, Wilbert S.

Systemic hypertension remains one of the leading cause of morbidity and mortality in the United States and throughout the world. Baxdrostat (CIN-107), a new drug developed by Roche is a selective aldosterone synthase inhibitor that is being evaluated as one of the potential treatments for hypertension, especially in patients with drug treatment-resistant hypertension. An increased level of aldosterone is associated with inflammation, systemic hypertension, and organ fibrosis, contributing to adverse cardiovascular events. A phase 2 trial, BrigHTN, showed promising results in demonstrating the efficacy of baxdrostat, where The HALO (efficacy and safety of baxdrostat in patients with uncontrolled hypertension) trial did not demonstrate any blood pressure-lowering benefit of baxdrostat when compared with the placebo. Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent.

2025-05-01·American Journal of Cardiovascular Drugs

Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat

Review

作者: Huston, Jessica ; Kumar, Ashish ; Ashchi, Andrew ; Bisharat, Mohannad ; Orey, Dontia ; Alkhouri, Yazan ; Sutton, David ; Deeb, Wasim ; Berner, Jason ; Ashchi, Andrea ; Goldfaden, Rebecca F

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.

141

项与 Baxdrostat 相关的新闻（医药）

2025-07-14

·氨基观察

减少嗜睡！武田新药两项关键III期成功；百利天恒定增过审，拟募集不超过39亿元

氨基观察-创新药组原创出品作者 | 黄恺嗜睡患者潜在新选择。7月14日，武田宣布，其口服食欲素受体2（OX2R）选择性激动剂 oveporexton（TAK-861）治疗 1型发作性睡病的两项关键III期 FirstLight 和 RadiantLight 研究达到所有主要和次要终点。百利天恒募资忙。日前，百利天恒公告表示，再融资申请获上交所通过，拟拟向特定对象发行A股股票并募集资金不超过39亿元（含本数），扣除发行费用后，实际募集资金将全部用于创新药研发项目。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。/ 01 /资本信息1）众生药业上半年净利同比预增94.49%-140.25%7月14日，众生药业公告，预计2025年半年度归属于上市公司股东的净利润为17,000万元–21,000万元，比上年同期增长94.49%～140.25%。2）百利天恒定增过审，拟募集不超过39亿元用于研发日前，百利天恒公告表示，再融资申请获上交所通过，拟拟向特定对象发行A股股票并募集资金不超过39亿元（含本数），扣除发行费用后，实际募集资金将全部用于创新药研发项目。3）通化东宝扭亏为盈7月14日，通化东宝公告，预计2025年半年度实现归属于上市公司股东的净利润约为21734.67万元，与上年同期相比，将实现扭亏为盈。/ 02 /医药动态1）宇道生物NTS071片获临床许可7月14日，据CDE官网，宇道生物NTS071片获临床许可，拟开展治疗携带TP53 Y220C突变的晚期实体瘤研究。2）挑战全球一线治疗，复宏汉霖HLX22头对头III期临床美国首例患者给药7月14日，复宏汉霖宣布，创新型抗HER2单抗HLX22头对头对比一线标准疗法（曲妥珠单抗+化疗±帕博利珠单抗）的国际多中心III期研究，完成美国首例患者给药，拟用于联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌。目前，全球尚无同类用于治疗HER2阳性胃癌的HER2双靶向疗法获批准上市。/ 03 /海外药闻1）难治性高血压新药取得突破，阿斯利康潜在重磅疗法Baxdrostat临床试验告捷日前，阿斯利康宣布，其试验阶段的高血压药物Baxdrostat能有效降低难治性或控制不佳的高血压患者的血压。在一项晚期临床试验中，患者每日服用两种不同剂量的Baxdrostat或安慰剂。12周后，服用Baxdrostat的患者收缩压(反映心脏向动脉泵血的压力)出现显著且具有临床意义的下降。2）减少嗜睡！武田小分子新药两项关键III期成功7月14日，武田宣布，其口服食欲素受体2（OX2R）选择性激动剂 oveporexton（TAK-861）治疗 1型发作性睡病的两项关键III期 FirstLight 和 RadiantLight 研究达到所有主要和次要终点。PS：欢迎扫描下方二维码，添加氨基君微信号交流。

临床3期财报申请上市临床2期

2025-07-14

·阿斯利康中国

Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN Ⅲ期临床试验中，达到主要及全部次要终点

与安慰剂相比，Baxdrostat展现出统计学且具临床意义的收缩压降低重磅发布BaxHTN III期试验的阳性结果显示，与安慰剂相比，两种剂量（2毫克和1毫克）的Baxdrostat在治疗12周时，患者坐位收缩压（SBP）均出现具有统计学意义和临床意义的显著降低，该试验还成功达到了所有次要终点。未控制或难治性高血压患者在标准治疗的基础上接受了Baxdrostat或安慰剂治疗。Baxdrostat 总体安全性和耐受性良好。全球有13亿高血压患者1。若血压未受控制，可能显著增加心脏疾病，卒中，心力衰竭和肾脏疾病的风险2, 3。在美国，约50%接受多种药物治疗的高血压患者仍无法控制血压4。越来越多的证据表明，醛固酮失调是高血压的关键生物学驱动因素之一5, 6。Bryan Williams 博士伦敦大学学院医学主席、首席研究员许多人即使服用多种药物，仍在与血压控制做斗争。BaxHTN III期结果极具前景，表明在标准治疗基础上加用每日一次的Baxdrostat可显著降低收缩压，为控制高血压这一心血管疾病的主要风险因素提供了一种潜在的新疗法。Sharon Barr阿斯利康全球执行副总裁，全球生物制药研发负责人BaxHTN III期试验取得了令人振奋的结果。数据显示，Baxdrostat能显著且具临床意义地降低收缩压。这一发现证实了baxdrostat通过靶向醛固酮失调，有望解决该关键的未满足需求，为这个二十余年来缺乏创新的领域带来了新的机制。BaxHTN是一项多中心、随机、双盲、安慰剂对照、平行分组的 III 期研究，旨在评估Baxdrostat在接受两种不同降压药物治疗但血压仍控制不佳的高血压患者，以及接受三种或以上降压药物（其中包括一种利尿剂）治疗但血压仍控制不佳的高血压患者中的安全性、耐受性及疗效7。研究数据将提交至全球各监管机构，并在2025年8月在欧洲心脏病学会（ESC）年会最新突破性研究专场进行汇报。Baxdrostat 是一种有望成为首创新药的高选择性的醛固酮合成酶抑制剂（ASI），靶向作用于导致血压升高及心血管和肾脏风险增加的激素。目前，该药正在作为单药疗法针对高血压8, 9和原发性醛固酮增多症10开展临床试验评估，同时与达格列净联用治疗慢性肾脏病，并用于高危高血压患者心力衰竭的预防11-13。难以控制的高血压高血压是一种以血压持续升高为特征的临床综合征2, 3。长期高血压可损伤血管及重要器官，增加出现严重健康问题的风险。高血压的控制仍然是一项重大公共卫生挑战。即便接受生活方式干预及多药联合治疗，多数高血压患者仍未能实现血压达标1, 4。其中，经两种及以上降压药物治疗仍未控制者为未控制高血压，而更严重的患者经三种及以上药物治疗血压仍持续升高则定义为难治性高血压2, 4。醛固酮作为调控血压的关键激素，通过促进钠水潴留机制升高血压，是高血压难以控制的重要致病因素5, 6。醛固酮水平升高，合并有肥胖、高盐摄入量以及各种遗传和继发性疾病14等因素，与血压控制不佳密切相关，若不及时治疗，会显著增加心脏病发作、卒中和肾功能衰竭的风险2, 3。BaxHTN 临床试验简要试验分为三个阶段，支持以下终点设定：在 12 周的双盲安慰剂对照期内评估主要终点。796位患者按 1:1:1 的比例随机接受Baxdrostat 2 毫克、1 毫克或安慰剂治疗，每日一次。主要疗效终点定义为第12周时，Baxdrostat治疗组（分别包括2毫克与1毫克）与安慰剂组患者坐位收缩压（SBP）较基线变化的均值差异。在第 24 周至第 32 周的随机停药期间，对疗效的持续性进行了评估。约300名原先接受 Baxdrostat 2毫克的患者再次按2:1比例再次随机分组，继续接受Baxdrostat 2毫克或转为安慰剂治疗8周。比较 8 周结束时Badrostat 2mg剂量组和安慰剂组坐位收缩压（SBP）差异。在52周研究结束时，与标准治疗组进行安全性对比评估。其他次要终点包括：在难治性高血压亚组中，Baxdrostat 与安慰剂在第 12 周时对坐位收缩压（SBP）的影响；Baxdrostat 与安慰剂在第 12 周时对坐位舒张压的影响；第12周实现坐位收缩压<130 mmHg的患者比例以及不良事件发生率。关于 BaxdrostatBaxdrostat 是一种有望成为首创新药的高选择性、强效口服小分子药物，可抑制醛固酮合酶15，该酶由 CYP11B2 基因编码，负责肾上腺中醛固酮的合成5。临床研究表明，Baxdrostat 可在较大剂量范围内显著降低醛固酮水平且不影响皮质醇水平16, 17。目前，该药正在作为单药疗法针对高血压7-9和原发性醛固酮增多症10开展临床试验评估，以及与达格列净联合用于治疗慢性肾病11, 12并用于高血压患者心力衰竭的预防13。阿斯利康（AstraZeneca）于2023年2月通过收购 CinCor Pharma 公司获得 Baxdrostat18。若在美国或欧洲提交新药申请，原CinCor股东将获得每股10美元现金（合计5亿美元）的或有价值付款。关于阿斯利康心血管、肾脏及代谢治疗领域心血管、肾脏及代谢始终是阿斯利康从全球到中国深耕的重要治疗领域和增长引擎。阿斯利康通过科学研究，深入了解心脏、肾脏和胰腺之间的潜在联系，积极投身于创新药物的研发，来有效保护器官，减缓甚至阻止疾病进展，最终让再生疗法成为可能。阿斯利康致力于通过更好地理解心血管、肾脏及代谢疾病之间的相互关联，从疾病的驱动机制着手，为患者提供更早、更有效地检测、诊断和治疗方案，从而改善和挽救数百万人的生命。关于阿斯利康阿斯利康（LSE/STO/Nasdaq: AZN）是一家科学至上的全球生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病以及包括心血管肾脏及代谢、呼吸及免疫在内的生物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。内容来源：新闻稿 (内部审批号:CN-163996）参考文献（滑动查看更多）1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population representative studies with 104 million participants. Lancet. 2021;398(10304):957-980.2. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. EurHeart J. 2024;45(38):3912-4018.3. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324.4. Carey RM, et al. Prevalence of apparent treatment-resistant hypertension in the United States: comparison of the 2008 and 2018 American Heart Association scientific statements on resistant hypertension [including online supplement]. Hypertension. 2019;73(2):424-431.5. Cannavo A, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular physiology and pathophysiology. Oxid Med Cell Longev. 2018;2018:1204598.6. Inoue K, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis [including online supplement]. Hypertension. 2020;76(1):113-120.7. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxHTN). Available at: https://clinicaltrials.gov/study/NCT06034743. Accessed June 2025.8. ClinicalTrials.gov. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (Bax24). Available at: https://clinicaltrials.gov/study/NCT06168409. Accessed June 2025.9. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (BaxAsia). Available at: https://clinicaltrials.gov/study/NCT06344104. Accessed June 2025.10. ClinicalTrials.gov. A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism (BaxPA). Available at: https://clinicaltrials.gov/study/NCT07007793. Accessed June 2025.11. ClinicalTrials.gov. A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific). Available at: https://clinicaltrials.gov/study/NCT06742723. Accessed June 2025.12. ClinicalTrials.gov. A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. Available at: https://clinicaltrials.gov/study/NCT06268873. Accessed June 2025.13. ClinicalTrials.gov. A Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (Prevent-HF). ClinicalTrials.gov identifier: NCT06677060. Available at: https://clinicaltrials.gov/study/NCT06677060. Accessed June 2025.14. van Oort S, et al. Association of cardiovascular risk factors and lifestyle behaviors with hypertension: a mendelian randomization study. Hypertension. 2020;76(6):1971-1979.15. Bogman K, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69:189-96.16. Freeman, MW et al. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;(46)108–118.17. Freeman MW, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. NEJM. 2023;388:395-40518. AstraZeneca 2023. Acquisition of CinCor Pharma complete. Available at: https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html. Accessed June 2025.

临床3期临床成功临床结果临床失败

2025-07-14

·医药经济报

AZ降压药数据积极，拜耳新药在英上市，诺诚健华在美IND

1.阿斯利康高血压创新药Ⅲ期试验数据积极7月14日，阿斯利康宣布旗下高选择性醛固酮合成酶抑制剂baxdrostat的III期BaxHTN研究达到主要终点和所有次要终点。试验结果显示，与安慰剂相比，两种剂量（2mg和1mg）的baxdrostat在12周时均显示出坐位收缩压（SBP）平均值的统计学显著和临床上有意义的降低。BaxHTN是一项III期、多中心、随机、双盲、安慰剂对照、平行组研究，旨在评估baxdrostat在接受两种不同降压药治疗的未控制高血压患者和接受三种或更多不同降压药（其中一种是利尿剂）治疗的顽固性高血压患者中的安全性、耐受性和效果。该药系阿斯利康于2023年以18亿美元收购CinCor公司获得。2.拜耳更年期潮热新药在英上市近日，拜耳宣布英国药品和医疗保健产品监管局（MHRA）批准旗下非激素类神经激肽-1，3（NK-1，3）双重受体拮抗剂elinzanetant上市，用于治疗与更年期相关的中重度血管舒缩症状（VMS，也称为潮热）。更年期症状如潮热，可能对女性的生活质量产生深远影响。它们不仅仅是身体上的不适，还可能严重扰乱日常活动、睡眠和情绪健康。据悉，此为该药在全球范围内的首次批准，其依据是 III 期研究 OASIS-1、-2 和 -3 的积极结果，这些研究评估了 elinzanetant 的有效性和安全性，其在3项研究中均达到了所有主要终点，并显示出良好的安全性。3.诺诚健华BCL2抑制剂在美获批临床7月14日，诺诚健华宣布，公司自主研发的新型BCL2抑制剂mesutoclax（ICP-248）联合阿扎胞苷治疗髓系恶性肿瘤，包括急性髓系白血病（AML）和骨髓增生异常综合征（MDS），已获得美国FDA批准开展临床研究。据公司资料，BCL2是细胞凋亡通路的重要调控蛋白，其表达异常与多种恶性血液肿瘤的发生发展相关。Mesutoclax通过选择性地抑制BCL2，恢复肿瘤细胞程序性死亡机制，发挥抗肿瘤疗效。来源：公司官网编辑：张洁莹版式编辑：于成林审校：马飞、张松医保飞检来袭！医院、药店这些领域将被重点核查饮片标注保质期，8月1日起强制执行五年3次100亿美元大并购！默沙东将在何处培育“新药王”？www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

临床3期并购临床申请

100 项与 Baxdrostat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
醛固酮增多症	临床3期	加拿大	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	德国	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	意大利	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	西班牙	AstraZeneca PLC	2025-08-07
醛固酮增多症	临床3期	英国	AstraZeneca PLC	2025-08-07
心脏衰竭	临床3期	美国	AstraZeneca PLC	2025-03-14
心脏衰竭	临床3期	中国	AstraZeneca PLC	2025-03-14
心脏衰竭	临床3期	日本	AstraZeneca PLC	2025-03-14
心脏衰竭	临床3期	阿根廷	AstraZeneca PLC	2025-03-14
心脏衰竭	临床3期	澳大利亚	AstraZeneca PLC	2025-03-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05432167 (CTgov)	临床2期	高血压 \| 慢性肾病	195	Placebo	淵願選壓願構簾範醖艱(壓餘淵繭鏇衊選餘鏇壓) = 網蓋蓋膚淵獵餘製積鹽獵選構糧範範構積壓繭 (淵範窪憲構遞範願艱獵, 2.231) 更多	-	2025-05-20
NCT05459688 (CTgov)	临床2期	高血压	175	CIN-107	鑰醖構艱積遞壓淵繭遞 = 網繭鹽構衊範獵網艱鬱鏇壓顧餘蓋顧襯簾範鑰 (繭鏇餘淵憲壓夢齋積夢, 襯繭齋網襯鏇鬱鹹構選 ~ 窪構積廠獵願鹹壓窪範) 更多	-	2024-12-16
NCT05137002 (HALO, CTgov)	临床2期	高血压	249	Placebo (Placebo)	夢衊願齋鏇繭範簾醖製(餘鏇遞繭鏇夢築觸範鏇) = 範鏇範蓋艱製膚夢鹹鑰鬱膚夢鏇遞網鹹繭淵選 (範製範衊醖鹽壓齋選廠, 1.58) 更多	-	2023-08-01
NCT05137002 (HALO, CTgov)	临床2期	高血压	249	CIN-107 (CIN-107 0.5 mg)	夢衊願齋鏇繭範簾醖製(餘鏇遞繭鏇夢築觸範鏇) = 餘醖艱遞襯餘選糧膚鏇鬱膚夢鏇遞網鹹繭淵選 (範製範衊醖鹽壓齋選廠, 1.63) 更多	-	2023-08-01
NCT04519658 (BrigHTN, Pubmed \| N Engl J Med)	临床2期	难治性高血压	248	Baxdrostat 0.5 mg	膚衊艱製簾觸窪鬱淵蓋(顧廠鑰夢構遞範製構齋) = 鬱範膚壓鑰積膚觸顧衊獵積鏇壓鹹鹽廠糧鏇築 (觸願齋觸餘鬱齋顧積鬱 )	积极	2023-02-02
NCT04519658 (BrigHTN, Pubmed \| N Engl J Med)	临床2期	难治性高血压	248	Baxdrostat 1 mg	膚衊艱製簾觸窪鬱淵蓋(顧廠鑰夢構遞範製構齋) = 鹹衊構膚繭觸鏇選觸獵獵積鏇壓鹹鹽廠糧鏇築 (觸願齋觸餘鬱齋顧積鬱 )	积极	2023-02-02
NCT05470725 (ASN2022) 人工标引	临床1期	高血压 \| 慢性肾病	32	CIN-107	淵廠繭廠鑰鏇窪襯鬱醖(鬱簾衊淵構選糧鏇窪窪) = only one mild drug-related adverse event (diarrhea) occurred 鑰艱餘觸壓鹽衊鹽繭網 (膚範觸齋窪築窪願糧選 )	积极	2022-11-04